Skip to content

ParcelBio

YC W24 · Active · Elevated mRNA for transformative medicines.

Competitors

Adjacent

Also from W24

All of W24

About ParcelBio

ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.

YC batch
W24 · Winter 2024
Status, per YC
Active
Category
Other
Team size
6
Location
San Francisco, CA, USA
Checked
32m ago

YC tags: Gene Therapy, Synthetic Biology, Biotech, Therapeutics, Drug discovery

ParcelBio in W24: 248 companies, 83% AI

ParcelBio: questions

Which YC batch was ParcelBio in?

ParcelBio was in Y Combinator's Winter 2024 batch (W24).

Is ParcelBio still active?

Y Combinator lists ParcelBio as active.

Where is ParcelBio based?

ParcelBio lists San Francisco, CA, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.